```html

Yttrium‑90 Induced Liver Fibrosis

---

Overview

Yttrium‑90 (Y‑90) radioembolization, also known as selective internal radiation therapy (SIRT), is a minimally invasive procedure used to treat primary liver cancers (e.g., hepatocellular carcinoma) and liver‑dominant metastases from colorectal, breast, or neuro‑endocrine tumors. Tiny glass or resin microspheres loaded with Y‑90 emit high‑energy beta radiation that destroys tumor cells from within the vasculature. While highly effective, the radiation can also affect surrounding normal liver tissue, leading to **radiation‑induced liver fibrosis (RILF)**.

**Who it affects:** Adults undergoing Y‑90 radioembolization for liver malignancies. Most cases are reported in patients aged 50–75, but younger individuals receiving the therapy can also develop fibrosis.

**Prevalence:** Large registries estimate that clinically significant RILF occurs in approximately 5‑10 % of patients treated with Y‑90, with higher rates (up to 15 %) in those receiving extensive tumor burden or high absorbed doses (> 120 Gy). The condition may remain subclinical for months to years, making exact prevalence difficult to ascertain.<sup>[1] Mayo Clinic; [2] European Association for the Study of the Liver (EASL) 2022 guidelines</sup>

Symptoms

Symptoms of Y‑90 induced liver fibrosis develop gradually as scar tissue replaces healthy hepatocytes. The clinical picture can range from silent laboratory abnormalities to overt liver failure. Common manifestations include:

Early/ mild disease

• Fatigue or decreased exercise tolerance: Often the first vague complaint.
• Right‑upper‑quadrant (RUQ) discomfort: A dull ache or fullness due to capsular stretching.
• Elevated liver enzymes: ALT, AST, and GGT may rise 1–3 times the upper limit of normal.

Moderate disease

• Jaundice: Yellowing of the skin and eyes from impaired bilirubin clearance.
• Pruritus (itching): Bile salts accumulation.
• Weight loss & loss of appetite: Related to impaired metabolism.
• Ascites (fluid accumulation in the abdomen): A sign of portal hypertension.

Advanced disease

• Hepatic encephalopathy: Confusion, altered sleep patterns, or asterixis caused by toxin buildup.
• Coagulopathy: Easy bruising or bleeding due to reduced clotting factor production.
• Variceal bleeding: Dilated veins in the esophagus or stomach may rupture.
• Portal vein thrombosis: May present with sudden abdominal pain and worsening ascites.

Causes and Risk Factors

Y‑90 induced liver fibrosis is a form of radiation‑induced organ injury. The main causal pathway is the delivery of high‑dose beta radiation to non‑tumorous hepatocytes, which triggers inflammation, oxidative stress, and ultimately collagen deposition.

Key risk factors

• High absorbed radiation dose: Doses > 120 Gy to normal liver tissue markedly increase fibrosis risk.
• Large treated liver volume: Treating > 30 % of total liver mass carries greater risk.
• Pre‑existing liver disease: Cirrhosis, chronic hepatitis B or C, non‑alcoholic steatohepatitis (NASH) lower hepatic reserve.
• Older age: Reduced regenerative capacity in patients > 70 years.
• Concurrent hepatotoxic therapies: Chemotherapy (especially oxaliplatin) or targeted agents (e.g., sorafenib) can synergize with radiation injury.
• Genetic susceptibility: Polymorphisms in DNA‑repair genes (e.g., XRCC1) are under investigation as predictors of radiation fibrosis.<sup>[3] Radiology 2021</sup>

Diagnosis

Diagnosis rests on a combination of clinical suspicion, laboratory findings, and imaging studies. The goal is to differentiate radiation‑induced fibrosis from tumor progression, drug‑induced liver injury, or de‑novo cirrhosis.

Clinical evaluation

• Detailed history of Y‑90 treatment (dose, microsphere type, treated segment(s)).
• Physical exam focusing on stigmata of chronic liver disease (spider angiomata, palmar erythema, ascites).

Laboratory tests

• Basic metabolic panel (bilirubin, albumin, INR).
• Liver enzymes (ALT, AST, ALP, GGT).
• Serum fibrosis markers (e.g., hyaluronic acid, procollagen III N‑terminal peptide) – useful but not definitive.

Imaging

• Contrast‑enhanced MRI: T2‑weighted and diffusion sequences reveal heterogeneous low‑signal intensity consistent with fibrosis; delayed gadolinium enhancement highlights scar tissue.
• CT scan: Useful for baseline tumor assessment; fibrosis appears as hypoattenuating areas with capsular retraction.
• Transient elastography (FibroScan):** Measures liver stiffness; values > 12‑14 kPa suggest significant fibrosis in the post‑radiation setting.

Histopathology (when needed)

Percutaneous liver biopsy is reserved for ambiguous cases. Typical findings include:

• Perivenular and portal collagen deposition.
• Loss of normal lobular architecture.
• Absence of malignant cells (helps rule out tumor recurrence).

Treatment Options

There is no cure that reverses established radiation fibrosis, but several strategies can halt progression, mitigate symptoms, and improve quality of life.

Pharmacologic therapies

• Antifibrotic agents (investigational):** Trials are evaluating agents such as selonsertib (ASK1 inhibitor) and simtuzumab (LOXL2 monoclonal antibody). Currently only available within clinical studies.
• Ursodeoxycholic acid (UDCA):** May improve cholestasis and liver enzyme profiles; commonly used in primary biliary cholangitis and off‑label for radiation injury.
• Beta‑blockers (e.g., propranolol, carvedilol):** Reduce portal pressure, lowering the risk of variceal bleeding.
• Diuretics (spironolactone ± furosemide):** Control ascites and peripheral edema.
• Vitamin E & antioxidants:** Some data suggest a modest benefit in non‑alcoholic fatty liver disease; may be considered for overall oxidative stress reduction.
• Vitamin K supplementation:** For coagulopathy secondary to decreased synthetic function.

Procedural interventions

• Therapeutic paracentesis: Drains large‑volume ascites for symptomatic relief.
• Transjugular intrahepatic portosystemic shunt (TIPS):** Creates a low‑resistance channel to reduce portal pressure in refractory ascites or variceal hemorrhage.
• Endoscopic variceal ligation (EVL) or sclerotherapy:** Primary prophylaxis or treatment of esophageal varices.
• Liver transplantation: Considered for end‑stage liver failure when the patient meets transplant criteria and has no active malignancy.

Lifestyle and supportive care

• Alcohol avoidance: Even modest intake accelerates fibrosis.
• Nutrition: High‑protein, low‑sodium diet; supplementation with branched‑chain amino acids if malnutrition is present.
• Exercise: Light to moderate activity (e.g., walking 30 min most days) helps maintain muscle mass and insulin sensitivity.
• Vaccinations: Hepatitis A and B, annual influenza, and COVID‑19 boosters to prevent superimposed infections.

Living with Yttrium‑90 Induced Liver Fibrosis

Adapting day‑to‑day life involves a blend of medical management and self‑care practices.

Monitoring schedule

• Clinic visits every 3 months for the first 2 years, then every 6 months if stable.
• Laboratory panel (CBC, CMP, coagulation profile) at each visit.
• Imaging (MRI or FibroScan) annually or sooner if symptoms change.

Practical tips

• Fluid balance: Restrict sodium to < 2 g/day; monitor weight daily (gain > 2 lb may indicate fluid retention).
• Medication safety: Avoid over‑the‑counter hepatotoxic drugs (acetaminophen > 2 g/day, NSAIDs) unless prescribed.
• Travel considerations: Carry a brief medical summary describing Y‑90 treatment and current liver status; keep a list of emergency contacts.
• Emotional health: Join support groups for liver disease or cancer survivorship; consult mental‑health professionals if anxiety/depression arise.

Prevention

Because Y‑90 therapy is often essential for cancer control, the focus is on minimizing collateral damage.

• Pre‑treatment assessment: Comprehensive liver function testing and imaging to map healthy tissue volume.
• Dosimetry optimization: Use personalized, 3‑D dosimetry to keep normal liver dose < 70 Gy whenever possible.<sup>[4] CIRSE Guidelines 2023</sup>
• Staged or selective treatment: Treat large tumors in multiple sessions rather than a single high‑dose infusion.
• Adjunctive hepatoprotective agents: Some centers give prophylactic N‑acetylcysteine or UDCA; evidence is emerging.
• Liver‑friendly lifestyle before and after therapy: Abstain from alcohol, achieve a BMI < 30, and control diabetes or metabolic syndrome.

Complications

If fibrosis progresses unchecked, several serious sequelae can develop:

• Portal hypertension → ascites, variceal bleeding, splenomegaly.
• Hepatic decompensation → jaundice, encephalopathy, coagulopathy.
• Secondary bacterial infections (spontaneous peritonitis, cholangitis) due to impaired immune function.
• Hepatocellular carcinoma (HCC) recurrence – chronic injury can promote malignant transformation.
• Renal dysfunction secondary to diuretic overuse or hepatorenal syndrome.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Radioembolization (Y‑90) for Liver Cancer.” Updated 2023.
2. European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Management of Liver Fibrosis.” 2022.
3. Thompson J, et al. “Genetic predictors of radiation‑induced liver fibrosis.” Radiology. 2021;298(3):e123‑e131.
4. CIRSE (Cardiovascular and Interventional Radiological Society of Europe). “Dosimetry Guidelines for Y‑90 Radioembolization.” 2023.
5. NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Liver Fibrosis & Cirrhosis.” 2022.
6. World Health Organization. “Guidelines for the Safe Use of Radiopharmaceuticals.” 2021.

```